Efficacy and Safety of Neoadjuvant Long-course Chemoradiation Plus Tislelizumab in Mid-low Locally Advanced Rectal Cancer: a Phase II, Multi-center, Open-label, Randomized Controlled Trial (POLARSTAR Trial)
Latest Information Update: 10 Mar 2025
At a glance
- Drugs Tislelizumab (Primary) ; Capecitabine; Programmed cell death-1 ligand-1 inhibitors
- Indications Adenocarcinoma; Rectal cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms POLAR-STAR
Most Recent Events
- 01 Feb 2025 Primary endpoint has been met (pCR rate) , according to Results published in the Nature Medicine
- 01 Feb 2025 Results (n=186) from phase II portion published in the Nature Medicine
- 04 Jun 2024 Results assessing the efficacy and safety of adding PD1 inhibitors to the neoadjuvant long-course chemoradiation of LARC patients with this phase 2, randomized, controlled trial were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.